UMB Bank n.a. Has $62,000 Stock Position in Sanofi (NASDAQ:SNY)

UMB Bank n.a. lifted its stake in shares of Sanofi (NASDAQ:SNYFree Report) by 30.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,124 shares of the company’s stock after purchasing an additional 264 shares during the quarter. UMB Bank n.a.’s holdings in Sanofi were worth $62,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Van ECK Associates Corp raised its position in Sanofi by 18.1% in the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company’s stock valued at $31,965,000 after purchasing an additional 101,726 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Sanofi by 128.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company’s stock worth $5,558,000 after purchasing an additional 64,747 shares in the last quarter. Geode Capital Management LLC increased its holdings in Sanofi by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company’s stock worth $12,427,000 after purchasing an additional 2,917 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Sanofi by 8.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 151,945 shares of the company’s stock worth $7,328,000 after purchasing an additional 12,440 shares in the last quarter. Finally, IFP Advisors Inc grew its stake in Sanofi by 17.2% in the fourth quarter. IFP Advisors Inc now owns 2,132 shares of the company’s stock valued at $103,000 after acquiring an additional 313 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the topic of several analyst reports. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective on the stock. Guggenheim reiterated a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. Finally, BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price objective on the stock. Three analysts have rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $61.50.

Check Out Our Latest Stock Report on Sanofi

Sanofi Stock Performance

NASDAQ SNY opened at $49.67 on Friday. The stock has a market capitalization of $121.81 billion, a PE ratio of 19.95, a P/E/G ratio of 1.01 and a beta of 0.50. The business has a 50 day simple moving average of $51.49 and a two-hundred day simple moving average of $52.01. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNYGet Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sanofi’s revenue was down 11.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.78 EPS. On average, research analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Stockholders of record on Friday, May 9th were issued a $2.0369 dividend. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.48. Sanofi’s payout ratio is 57.14%.

About Sanofi

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.